Back to search results

A Study of LY4006896 for Parkinson's Disease

This study is testing a drug called LY4006896, given through a vein (intravenously or IV), compared to a placebo (an inactive substance) in healthy volunteers and people with Parkinson's disease. The main goal is to understand if LY4006896 is safe and how well your body handles it. Researchers will be looking for any serious side effects or other side effects that happen during the study. The study aims to enroll 127 participants aged 30 to 85 years old. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 127 participants. It compares LY4006896 given intravenously to a placebo.
What's involved
If you have Parkinson's disease, your screening period could be up to 120 days, followed by treatment and follow-up for up to 61 weeks. If you are a healthy participant, your screening period could be up to 35 days, followed by treatment and follow-up for up to 48 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants with Parkinson's disease will be followed for up to 61 weeks after starting treatment. Healthy participants will be followed for up to 48 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06809400

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Recruiting
PHASE1Ages 30–85InterventionalTreatment
Eli Lilly and Company
~127 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:LY4006896Placebo

At a glance

Recruiting sites
11 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part A
Measured over Baseline to Week 48
+3 more outcomes measured

Conditions

Parkinson Disease

Explore related trials

Parkinson Disease

NCT06809400

Where you'd take part

This study runs at 14 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Aqualane Clinical Research

    Naples, Floridastudy coordinator listed

    Recruiting

  • Charter Research

    Orlando, Floridastudy coordinator listed

    Recruiting

  • Charter Research

    The Villages, Floridastudy coordinator listed

    Recruiting

  • Collaborative Neuroscience Network - CNS

    Los Alamitos, Californiastudy coordinator listed

    Recruiting

  • Collaborative Neuroscience Network - CNS

    Los Alamitos, Californiastudy coordinator listed

    Recruiting

  • Evergreen Health Research

    Kirkland, Washingtonstudy coordinator listed

    Not yet recruiting

  • Inland Northwest Research

    Spokane, Washingtonstudy coordinator listed

    Not yet recruiting

  • K2 Medical Research, LLC

    The Villages, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a body mass index within the range of 18 to 34 kilogram/square meter (kg/m²) (inclusive).
For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.
Have venous access sufficient to allow for blood sampling or administration of study intervention for IV administration, or both.
Participant must be 30 to 85 years of age (inclusive), at the time of signing the informed consent
Are overtly healthy
For Chinese participants: To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be exclusive Chinese descent and born in China.
Participant must be 40 to 85 years of age (inclusive), at the time of signing the informed consent
Diagnosis of Parkinson's disease per United Kingdom (UK) Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.
If presently untreated for Parkinson's disease, clinical status is not expected to require changes in symptomatic treatment within 52 weeks from baseline.
If presently being treated for Parkinson's disease, receiving a stable dose of symptomatic dopaminergic therapy, including monoamine oxidase-B inhibitor, levodopa/carbidopa or dopamine agonist for at least 90 days prior to baseline and not expected to change within 52 weeks.
Have a Montreal Cognitive Assessment (MoCA) score of greater than or equal to (≥) 24.

Exclusion

Have significant neurological disease affecting the central nervous system (CNS) (other than Parkinson's disease in Part B cohorts) that may affect the participant's ability to complete the study.
Have a history or presence of serious or unstable illnesses or conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than 24 months.
Have known allergies to LY4006896, related compounds, or any components of the formulation, or history of allergic reactions to any transferrin receptor antibodies.
Have significant allergies to humanize monoclonal antibodies.
Have clinically significant multiple or severe drug allergies (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis); or intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions.
Have history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency.
Evidence of clinically significant anemia.
Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or a preexisting history of hypertension.
Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure \>150 mm Hg or a diastolic blood pressure \>95 mm Hg at Screening or Treatment Visits.
Have an implanted deep brain stimulation (DBS) system or any other implanted neurostimulation device (including but not limited to spinal cord stimulation, vagus nerve stimulation or investigational neuromodulation devices)
Are receiving continuous infusion therapy with anti-parkinsonian medications, including but not limited to subcutaneous foslevodopa-foscarbidopa, subcutaneous apomorphine, or intraduodenal/intestinal levodopa formulations

What this trial measures

  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part ABaseline to Week 48
  • Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) Part ABaseline to Week 48
  • Number of Participants with One or More SAEs Part BBaseline to Week 61
  • Number of Participants with One or More TEAEs Part BBaseline to Week 61